论文部分内容阅读
目前肺癌的生物靶向治疗已进入临床治疗阶段,以吉非替尼、厄洛替尼和西妥昔单抗为代表的抗表皮生长因子受体(epidermal growth factor receptor,EGFR)通路的药物和以贝伐单抗为代表的抗血管内皮细胞生长因子受体(vascular endothelialcell growth factor receptor,VEGFR)通路的药物已成功地应用于肺癌临床治疗。然而,肺癌分子生物学机制十分复杂,以EGFR和VEGFR信号通路为靶点的治疗存在局限和不足。近年来,肺癌新的分子生物靶点逐渐受到关注,例如棘皮动物微管相关蛋白4/间变淋巴瘤激酶(echinoderm microtubule-associated protein-like4/anaplastic lymphoma kinase,EML4-ALK)融合基因、哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)、胰岛素样生长因子Ⅰ型受体(insulin-like growth factor typeⅠreceptor,IGF-1R)和间质上皮转变因子(mesenchymal-epithelial transition factor,c-MET)等。本文对上述分子生物学标志物在肺癌治疗中的作用及其相关临床研究进展进行综述。
At present, the bio-targeted therapy of lung cancer has entered the clinical treatment phase. The drugs targeting epidermal growth factor receptor (EGFR) pathway represented by gefitinib, erlotinib and cetuximab and Bevacizumab as the representative of the vascular endothelial cell growth factor receptor (VEGFR) pathway drugs have been successfully used in the clinical treatment of lung cancer. However, the molecular mechanism of lung cancer is very complicated, and there are limitations and deficiencies in the treatment of EGFR and VEGFR signaling pathways. In recent years, new molecular biological targets of lung cancer have drawn increasing attention, such as the echinoderm microtubule-associated protein-like4 / anaplastic lymphoma kinase (EML4-ALK) fusion gene, the mammalian Mammalian target of rapamycin (mTOR), insulin-like growth factor type I receptor (IGF-1R) and mesenchymal-epithelial transition factor (c- MET) and so on. This article reviews the role of these molecular biomarkers in the treatment of lung cancer and the progress of their clinical research.